Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants ...
Detailed price information for Vir Biotechnology Inc (VIR-Q) from The Globe and Mail including charting and trades.
– Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented – Vir Biotechnology to ...
with the goal of delivering a new treatment to patients affected by this rare disease. Most importantly, it represents hope for HDV patients who lack effective treatment options." About Hepatitis D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback